Literature DB >> 10575280

[Does the study "Complementary medicine in health insurance" provide a basis for scientifically valid conclusions?].

G S Kienle1, H Kiene.   

Abstract

In Switzerland public attention was caught by a health economic analysis of health insurance's reimbursement of complementary medical procedures. Objectives of the study were 1) cost development, 2) health status development of insured citizens, 3) substitutional/additional use of complementary medical procedures. However, several conceptual, methodical and statistical flaws limit the conclusions that can be drawn from this study: The analysis claimed to be based on a large randomized trial. However, the attempt to achieve an unbiased equality in experimental and control group through stratified sampling grossly failed. Effects of complementary medical procedures on health status were inappropriately assessed and only based on 10 patients. The question whether complementary medicine is being used as a substitution or addition to conventional medicine was not even explored (the published result is based on a misleading interpretation of the health insurance's database). Finally, statements on cost developments were not based on estimations, but resulted from methodical and statistical artifacts. Furthermore, the study suffered from several other weaknesses, like a 50% dropout rate, an inadequate description of statistical procedures, an extremely reduced statistical power, and a lack of clear distinction between experimental and retrospective analyses. Therefore, no valid conclusions can be drawn from this study. Copyright 1999 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Year:  1999        PMID: 10575280     DOI: 10.1159/000021263

Source DB:  PubMed          Journal:  Forsch Komplementarmed        ISSN: 1021-7096


  1 in total

1.  Extent and structure of health insurance expenditures for complementary and alternative medicine in Swiss primary care.

Authors:  Andre Busato; Reiner Eichenberger; Beat Künzi
Journal:  BMC Health Serv Res       Date:  2006-10-11       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.